RESUMEN
BACKGROUND: This study aimed to explore the association of A-kinase interacting protein 1 (AKIP1) with chemokine (C-X-C motif) ligand (CXCL) 1/CXCL2, and further investigate their correlation with clinical features and prognosis in acute myeloid leukemia (AML) patients. METHODS: Totally 160 de novo AML patients were recruited, and their bone marrow samples were collected before treatment for detecting the expressions of AKIP1, CXCL1, and CXCL2 by the quantitative polymerase chain reaction. Complete remission (CR) was assessed after induction treatment, and event-free survival (EFS) and overall survival (OS) were calculated. RESULTS: AKIP1 expression was positively associated with CXCL1 (P < .001) and CXCL2 expression (P < .001). AKIP1 high expression was correlated with FAB classification (P = .022), monosomal karyotype (P = .001), and poor risk stratification (P = .013), while CXCL2 high expression was associated with monosomal karyotype (P = .001). As for treatment response, AKIP1 high expression exhibited a trend to be increased in non-CR patients compared with CR patients, while without statistical significance (P = .105). However, no correlation of CXCL1 (P = .418) or CXCL2 (P = .685) with CR achievement was observed. Most importantly, AKIP1 and CXCL1 were negatively correlated with accumulating EFS and OS (all P < .05), while CXCL2 only showed a trend to be negatively associated with accumulating EFS (P = .069) and OS (P = .055; but without statistical significance). CONCLUSION: AKIP1 might serve as a novel biomarker for worse AML prognosis through the interaction of CXCL1/CXCL2.
Asunto(s)
Proteínas Adaptadoras Transductoras de Señales/genética , Quimiocina CXCL1/genética , Quimiocina CXCL2/genética , Leucemia Mieloide Aguda/genética , Leucemia Mieloide Aguda/mortalidad , Proteínas Nucleares/genética , Adulto , Biomarcadores de Tumor/genética , Femenino , Regulación Leucémica de la Expresión Génica , Trasplante de Células Madre Hematopoyéticas , Humanos , Leucemia Mieloide Aguda/terapia , Masculino , Persona de Mediana Edad , Mutación , PronósticoRESUMEN
This study aimed at investigating the prevalence of anxiety and depression, and their risk factors as well as their correlation with prognosis in refractory or relapsed (R/R) acute myeloid leukemia (AML) patients.A total of 180âR/R AML patients were enrolled and their anxiety and depression were assessed by Hospital Anxiety and Depression Scale (HADS) before treatment. Besides, HADS was also evaluated in 180 de novo AML patients prior treatment and 180 healthy controls (HCs), respectively.Both the HADS-Anxiety and HADS-Depression scores were increased in R/R AML patients compared with de novo AML patients and HCs (all Pâ<â.001). Meanwhile, the prevalence of anxiety and depression was 53.9% and 45.6% in R/R AML patients, which were also greatly higher compared with de novo AML patients and HCs (all Pâ<â.01). Regarding risk factors, higher Eastern Cooperative Oncology Group score and lines of salvage therapy were correlated with anxiety and depression in R/R AML patients (all Pâ<â.05). Furthermore, anxiety and depression were associated with shorter overall survival (OS) in R/R AML patients (all Pâ<â.05), while no association of different degrees of anxiety and depression with OS was observed (all Pâ>â.05).Anxiety and depression are highly prevalent and implicated in the management and prognosis of R/R AML.